Results 41 to 50 of about 22,142 (188)

Posaconazole-ibrutinib interaction cannot be avoided by staggered dosing : How to optimize ibrutinib dose during posaconazole treatment

, 2023
Aims: Ibrutinib is used in the treatment of certain B-cell malignancies. Due to its CYP3A4-mediated metabolism and highly variable pharmacokinetics, it is prone to potentially harmful drug-drug interactions.Methods: In a randomized, placebo-controlled ...
Tornio, Aleksi, Olkkola, Aleksi M., Kiiski, Johanna I., Niemi, Mikko, Hauta-aho, Milka, Neuvonen, Pertti J., Neuvonen, Mikko, Backman, Janne T., Tapaninen, Tuija, Lapatto-Reiniluoto, Outi   +9 more
core   +1 more source

A Novel Case of Penile Gangrene in a Patient Treated with Ibrutinib for Chronic Lymphocytic Leukemia

Case Reports in Oncological Medicine, 2016
Introduction. Ibrutinib is commonly used for the treatment of patients with CLL in either first-line or relapsed/refractory settings. Case Presentation.
William Paul Skelton IV, Neeka N. Akhavan, Zachary A. Taylor, Thu-Cuc Nguyen, Hassan Hassan, Tabitha N. Townsend, Prajwol Pathak, Gaurav Trikha, Nam H. Dang, Long H. Dang, Azka Ali   +10 more
doaj   +1 more source

Real-World Clinical Outcomes and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Single-Center Retrospective Study

Medicina, 2023
Background and Objectives: The treatment of chronic lymphocytic leukemia (CLL) has acquired new targeted therapies. In clinical trials, ibrutinib improved outcomes safely. Real-world data called for a reappraisal of ibrutinib strategies.
Ana-Maria Moldovianu, Razvan Stoia, Mariana Vasilica, Iulia Ursuleac, Sorina Nicoleta Badelita, Andra Alina Tomescu, Oana Diana Preda, Alexandru Bardas, Mihaela Cirstea, Daniel Coriu   +9 more
doaj   +1 more source

Repurposing FDA‐Approved Drugs to Inhibit Fungal PPTases for Broad‐Spectrum Synergy

Advanced Science, EarlyView.
Fungal secondary metabolites serve as crucial virulence effectors; however, the potential of their biosynthetic pathways as antifungal targets remains inadequately comprehended. Repurposed FDA‐approved drugs inhibit fungal PPTase (essential for secondary metabolism) in vivo.
Zili Song, Can Zhao, Qiaoling Wang, Hongjiao Zhang, Xiao Liu, Linqi Wang, Michael Bromley, Wen‐Bing Yin   +7 more
wiley   +1 more source

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. [PDF]

, 2015
BACKGROUND: Chronic lymphocytic leukemia (CLL) primarily affects older persons who often have coexisting conditions in addition to disease-related immunosuppression and myelosuppression. We conducted an international, open-label, randomized phase 3 trial
Burger, Jan A, Li, Jianyong, Barr, Paul M, Grosicki, Sebastian, Stevens, Don A, Gaidano, Gianluca, Robak, Tadeusz, Maslyak, Zvenyslava, Bairey, Osnat, Bartlett, Nancy L, Hillmen, Peter, McCarthy, Helen, Owen, Carolyn, Janssens, Ann, Tedeschi, Alessandra, Quach, Hang, Simpson, David, Van Den Neste, Eric, Coutre, Steven, Ghia, Paolo, Devereux, Stephen   +20 more
core   +3 more sources

Population Pharmacokinetic and Exposure‐Response Analyses of Ibrutinib Combined With Bendamustine and Rituximab in Patients With Mantle Cell Lymphoma

CPT: Pharmacometrics & Systems Pharmacology
Efficacy and safety of ibrutinib 560 mg once daily or placebo combined with bendamustine and rituximab (BR) were assessed in patients with mantle cell lymphoma in a randomized phase 3 study (SHINE).
Per Olsson Gisleskog, Belén Valenzuela, Nicoline Treijtel, Sanjay Deshpande, Todd Henninger, Juan José Perez‐Ruixo   +5 more
doaj   +1 more source

The synergistic impact of granulocytic myeloid‐derived suppressor cells and innate lymphoid cells in systemic sclerosis

Arthritis &Rheumatology, Accepted Article.
Objective Systemic sclerosis (SSc) is a chronic autoimmune disorder characterized by immune dysregulation and fibrosis, with myeloid‐derived suppressor cells (MDSCs) emerging as important regulators of immune responses. However, the role of MDSCs in SSc‐associated fibrosis and their interactions with other immune cell populations remain poorly ...
Stefanie Weber, Mario R. Angeli, Hashem Mohammadian, Hannah Labinsky, Maria Gabriella Raimondo, Richard Demmler, Yuko Ariza, Thomas Wohlfahrt, Markus Luber, Yi‐Nan Li, Jörg H.W. Distler, Tobias Bäuerle, Georg Schett, Simon Rauber, Andreas Ramming, Alina M. Ramming   +15 more
wiley   +1 more source

Status of oncology drugs with a conditional approval: A cross‐sectional comparison of the Food and Drug Administration and Health Canada

British Journal of Clinical Pharmacology, EarlyView.
Aims This study looks at the status of the same drugs conditionally approved by the Food and Drug Administration and Health Canada for the same oncology indication. Methods Lists of oncology drugs with a conditional approval from the Food and Drug Administration and Health Canada were generated and drug pairs with the same indication were matched ...
Joel Lexchin
wiley   +1 more source

Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemia

, 2019
Activation-induced cytidine deaminase (AID) initiates somatic hypermutation and class switch recombination of the immunoglobulin genes. As a trade-off for its physiological function, AID also contributes to tumor development through its mutagenic ...
Morande, Pablo Elías, Di Noia, Javier M., Burger, Jan A., Uriepero, Angimar, Fresia, Pablo, Sivina, Mariela, Berca, Catalina, Seija, Noé, Landoni, Ana Inés, Oppezzo, Pablo   +9 more
core   +1 more source

Ibrutinib-A double-edge sword in cancer and autoimmune disorders.

, 2016
Targeted therapies have appeared as new treatment options for several disease types, including cancer and autoimmune disorders. Of several targets, tyrosine kinases (TKs) are among the most promising.
Håkan Mellstedt (18681301), Abdolreza Sotoodeh Jahromi (19973223), Farhad Jadidi-Niaragh (7385609), Parviz Kokhaei (18681283), Mohammad Hojjat-Farsangi (400459), Anders Osterborg (19973226)   +5 more
core   +1 more source